MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/09546634.2022.2110836

Медицинская библиотека · The Journal of dermatological treatment · 2022

Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece.

Papadavid Evangelia, Zafeiriou Efterpi, Georgiou Sophia, Roussaki-Schulze Angeliki-Viktoria, Spiliopoulos Theofanis, Vryzaki Eleftheria, Oikonomou Chrysa, Drongoula Ourania, Boziou Maria, Goudouras Georgios, Sfaelos Konstantinos, Apalla Zoi, Lazaridou Elisavet

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To assess the real-world clinical treatment outcomes with brodalumab in patients with moderate-to-severe plaque psoriasis in Greece.

MATERIALS AND

METHODS

This was a longitudinal, retrospective, real-world analysis of data from medical records of 106 patients with moderate-to-severe plaque psoriasis, treated with brodalumab for up to 24 months at four University Dermatology Centers in Greece. Efficacy assessments of psoriasis severity [Psoriasis Area and Severity Index (PASI) and Body Surface Area affected (BSA) scores] and its impact on patients' quality of life (QoL) [Dermatology Life Quality Index (DLQI) score] were evaluated at different timepoints up to 24 months.

RESULTS

Treatment with brodalumab reduced both mean PASI (14.0-1.5, p < .001) and BSA scores (21.6-2.5, p < .001) across all visits. This effect was accompanied by reduction in mean DLQI score (12.8-2.1, p < .001) across all visits compared with baseline. Moreover, therapeutic efficacy was affected by prior biologic treatment exposure, as biologic naïve patients had greater reductions in all scores from baseline following treatment with brodalumab (numerical for mean PASI, significant for mean BSA and DLQI scores).

CONCLUSION

Brodalumab is effective long term, improving disease severity and health-related QoL in patients with moderate-to-severe plaque psoriasis in a real-world setting.

Для цитирования: Papadavid Evangelia, Zafeiriou Efterpi, Georgiou Sophia, Roussaki-Schulze Angeliki-Viktoria, Spiliopoulos Theofanis, Vryzaki Eleftheria, Oikonomou Chrysa, Drongoula Ourania, Boziou Maria, Goudouras Georgios, Sfaelos Konstantinos, Apalla Zoi, Lazaridou Elisavet. Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece.. The Journal of dermatological treatment. 2022. DOI: 10.1080/09546634.2022.2110836.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.